Dr. Pleyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
Bethesda, MD 20814Phone+1 216-444-2200
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
- Cleveland Clinic FoundationResidency, Internal Medicine, 2013 - 2016
- OtherClass of 2012
Certifications & Licensure
- CA State Medical License 2018 - 2026
- DC State Medical License 2018 - 2024
- OH State Medical License 2013 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 94 citationsEffect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.Christopher Pleyer, Mir A. Ali, Jeffrey I. Cohen, Xin Tian, Susan Soto
Blood. 2021-01-14 - 26 citationsRisk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodineRemco J. Molenaar, Christopher Pleyer, Tomas Radivoyevitch, Surbhi Sidana, Andrew Godley
Leukemia. 2018-04-01 - 23 citationsLysozyme amyloidosis - a case report and review of the literature.Christopher Pleyer, Jan Flesche, Fahad Saeed
Clinical Nephrology. Case Studies. 2015-12-28
Lectures
- Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's T...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: